Info

TRACON Pharmaceuticals, Inc. is a biotechnology company developing targeted therapies for cancer and related diseases. We address unmet needs in this arena with product candidates that focus on cellular targets primarily implicated in cancer growth and angiogenesis. Currently, TRACON is focused on the development of several drug candidates fitting this profile, all of which are at an early stage of development. We believe that these treatments have the potential to offer benefits far exceeding those provided by cytotoxic cancer treatments and first generation targeted therapies. Further, our drug candidates have been selected, in part, for their potentially advantageous side effect profile and will be developed with the goal, among other goals, of expanding the standard of care by combining easily with existing therapies. Our mission is to become a premier therapeutics company in oncology and related diseases. Our vision is to develop and commercialize targeted therapeutic products in underserved indications to maximize patient benefit and enhance shareholder value. In order to achieve this goal, our strategy is to:recruit a senior management team with a proven track record of success developing targeted therapeutics; apply our development expertise to develop and commercialize our drug candidates; leverage resources through collaborations and outsourcing; and enhance our pipeline by in-licensing additional attractive drug candidates. We have established partnerships with academic and commercial entities that have identified candidates in late preclinical or early clinical development for cancer and angiogenesis. Our business model is designed to avoid the expense and risk inherent in internal drug discovery programs and attempts to maximize value by improving upon identified candidates with appropriate scientific, development and commercial expertise, in order to advance them through preclinical development and clinical trials. We will attempt to optimize compounds by identifying clear clinical and regulatory pathways forward, strengthening and developing intellectual property ownership, and conducting pre-clinical and clinical development to produce pharmaceuticals that add value for patients, physicians and shareholders. TRACON was formed in New York, in October 2004, as Lexington Pharmaceuticals, Inc., a Delaware corporation. In March 2005, the Company's name was changed to TRACON Pharmaceuticals, Inc., and it moved from New York to San Diego, California. Dr. Bertrand C. Liang was named President and CEO of the Company at that time. With the initial infrastructure of the Company established over the ensuing year, Dr. Charles P. Theuer replaced Dr. Liang as President and CEO in July 2006.